Q3 2024 Jaguar Health Inc Earnings Call Transcript

Nov 13, 2024 / 01:30 PM GMT

Release Date Price: $864.15 (-9.39%)

Transcript 8-K10-Q

Key Points

Positve

Jaguar Health Inc (JAGX) reported a 4% increase in net revenue for Q3 2024 compared to Q2 2024, and an 11% increase compared to Q3 2023.
The company achieved significant results in a phase three trial for breast cancer patients, with data accepted for presentation at a major cancer symposium.
Jaguar Health Inc (JAGX) launched its third commercialized prescription product, GelClear, in the U.S., targeting oral mucositis, a common cancer treatment side effect.
The company is initiating multiple clinical trials for rare and orphan diseases, with potential early patient access programs in Europe.
Jaguar Health Inc (JAGX) has orphan drug designation for its product in both the U.S. and Europe, which could support early patient access before full regulatory approval.

Negative

The company reported a net loss attributable to common shareholders of $9.9 million for Q3 2024, an increase from $7.8 million in Q3 2023.
Jaguar Health Inc (JAGX) did not achieve the primary endpoint for all solid tumor types in its ambitious phase three trial.
The company's discussions with the FDA cannot be fast-tracked, potentially delaying regulatory approval processes.
Despite increased revenue, the company still faces significant operational losses, with a GAAP recurring EBITA net loss of $9.2 million for Q3 2024.
The company acknowledges the high cost and risk associated with clinical development, particularly for its late-stage products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

JAGX.OQ - Jaguar Health Inc
Q3 2024 Jaguar Health Inc Earnings Call
Nov 13, 2024 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company uncertainties. Regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives including products in the development stage, which may not, may not make achieve scientific objectives or meet stringent regulatory requirements.

Forward-looking statements are subject to risks and uncertainties that could cause actual results different materially from those complicated in such forward-looking statements. These statements are based on current available information and management's current

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.